Skip to main content
OpenTrials
Completed

NCT Number: NCT00146484

A Study of Two Versus Three Daily Injections in Children and Adolescents With Newly Diagnosed Type 1 Diabetes

The optimal insulin regimen for children and adolescents with newly diagnosed type 1 diabetes remains unknown. The purpose of this study is to determine whether a split evening injection regimen (insulin injections before breakfast, supper and bedtime) leads to better glucose control and quality of life than twice daily insulin in children and adolescents with new onset diabetes.

Completed

Looking for future studies?

Notify Me

Key information

Age range

Up to 17 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Children's Hospital of Eastern Ontario

Ottawa, Ontario, K1H 8L1, Canada

About this study

The optimal insulin regimen for children and adolescents with newly diagnosed type 1 diabetes remains unknown. No published studies have examined the effectiveness of a split evening (three times daily) injection regimen in this group of patients. Indeed, because the first few years of diabetes management are the easiest (due to a "honeymoon" period characterised by residual insulin secretion), the potential for any benefit from more intensive management (i.e., three daily injections) may be small during this period. In addition, the intensity of the initial insulin regimen may be an important determinant of quality of life, family functioning, and subsequent compliance with diabetes regimens. A randomized controlled trial has been designed to test the hypothesis that a split evening injection regimen leads to better glycemic control and quality of life than twice daily insulin in children and adolescents with new onset diabetes.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • New onset type 1 diabetes
  • Less than 48 hours since first insulin injection
  • Child and/or parent able to read and write English
  • Family intends to continue treatment at our institution for the next two years
  • Informed consent from adolescents greater than 16 years of age, or if less than 16 years, informed consent from the parent/guardian with assent from the child.

Exclusion criteria

  • Chronic medical conditions other than treated hypothyroidism or mild asthma
  • Concerns of the diabetes team regarding future treatment adherence making twice daily insulin preferable to the split evening injection regimen (e.g., cognitive impairment, severe family dysfunction).

Treatment and study plan

Twice Daily versus Three Times Daily Insulin Injections

Drug

Primary outcomes

  1. * Hemoglobin A1c over the first 24 months of diabetes

Secondary outcomes

  1. * Frequency of hypoglycemia (mild and severe) over the first 24 months of diabetes

  2. * Frequency of morning hyperglycemia over the first 24 months of diabetes

  3. * Residual c-peptide at two years post diagnosis (stimulated c-peptide post Sustacal challenge)

  4. * Diabetes Quality of Life (DQOLY) over the first 24 months of diabetes

  5. * Family Functioning (Family Environment Scale)over the first 24 months of diabetes

Sponsors and collaborators

Lead sponsor

Children's Hospital of Eastern Ontario

Other

Registry information

Official study title

A Randomized Controlled Trial of Two Versus Three Daily Insulin Injections in Children and Adolescents With New Onset Type 1 Diabetes Mellitus

Important dates

Study start
1996
Study completion
2001
First posted
Sep 7, 2005
Registry last updated
Sep 7, 2005

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.